Lgr5 Lgr6 Markers for Stem Cell Isolation Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and identifying adult and cancer stem cells are inefficient, as existing markers are not specific enough, leading to impure populations and limited understanding of their properties and behavior.
Innovation Solution
The use of Lgr5 and Lgr6 surface molecules as markers to isolate adult and cancer stem cells, allowing for the enrichment of stem cell populations to over 90% purity, enabling effective isolation and potential therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If existing markers are used to isolate stem cells, then the isolation process is simple, but the purity of stem cell populations is low
Solution Approach 1:
The patent applies parameter changes by switching from traditional markers (such as CD34, CD133) to novel markers (LGR5, LGR6, PROM1) that exhibit different expression patterns on stem cells. This marker substitution enables significantly higher purification levels (over 90% purity) by selectively binding to stem cells while excluding other cell types, thereby resolving the contradiction between isolation simplicity and population purity.
2Loss of information
If traditional isolation methods are used, then the process is straightforward, but the understanding of stem cell properties is limited
Solution Approach 1:
The patent replaces traditional mechanical and non-specific chemical isolation methods with marker-specific molecular recognition systems. By using antibodies or ligands that specifically bind to LGR5, LGR6, or PROM1 markers on stem cell surfaces, the method enables both highly efficient isolation and simultaneous characterization of stem cell properties, thus eliminating the trade-off between information loss and productivity.
3Reliability
If non-specific markers are used, then isolation is easier, but the specificity for stem cells is insufficient
Solution Approach 1:
The patent introduces specific molecular intermediaries (antibodies or ligands targeting LGR5, LGR6, PROM1) that act as mediators between the isolation system and stem cells. These intermediaries provide high specificity by selectively recognizing and binding to stem cell markers, while the overall process remains operationally simple through standard flow cytometry or magnetic sorting techniques, thus resolving the contradiction between reliability and ease of operation.
Data Source
AI summary
The invention relates to the fields of biochemistry, pharmacy and oncology. The invention particularly relates to the use of novel stem cell markers for the isolation of stem cells. The invention further relates to the obtained stem cells and their use in for example research or treatment, for example, for the preparation of a medicament for the treatment of damaged or diseased tissue.In one of the embodiments, the invention provides a method for obtaining (or isolating) stem cells comprising optionally preparing a cell suspension from a tissue or organ sample, contacting said cell suspension with an Lgr 6 or 5 binding compound, identify the cells bound to said binding compound, and optionally isolating the stem cells from said binding compound.The invention further relates to means suitable for cancer treatment and even more specific for the treatment of cancer by eradicating cancer stem cells.